Metastatic spread to bone: The role of chemotherapy

Stefano Ferrari, Emanuela Palmerini, Andreas F. Mavrogenis, Pietro Ruggieri

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Genetic profiling of tumors has revealed important regulators of the metastatic process and suggested novel targets for cancer therapeutics. Targeting the tumor cell alone is not sufficient; multimodality therapy against tumor cells, their growth factors and the essential accessory cells with which cancer cells interact is imperative. In the bone marrow and within the tumor stroma, two niches constitute highly specific, physiologically defined sites; the vascular and stromal niche. A high preponderance of tumor cells is found in the bone marrow of patients with malignancy, even in the absence of overt distant metastases. Bisphosphonates inhibit normal and pathologic osteoclast-mediated bone resorption. Denosumab inhibits the maturation of osteoclasts by binding to RANKL, protecting the bone from degradation.

Original languageEnglish
Title of host publicationAdvances in Bone Metastasis Management
PublisherFuture Medicine Ltd.
Pages19-28
Number of pages10
ISBN (Print)9781780840307, 9781780841151
DOIs
Publication statusPublished - Mar 1 2012

Fingerprint

Bone and Bones
Drug Therapy
Neoplasms
Osteoclasts
Bone Marrow
Diphosphonates
Bone Resorption
Blood Vessels
Intercellular Signaling Peptides and Proteins
Neoplasm Metastasis
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ferrari, S., Palmerini, E., Mavrogenis, A. F., & Ruggieri, P. (2012). Metastatic spread to bone: The role of chemotherapy. In Advances in Bone Metastasis Management (pp. 19-28). Future Medicine Ltd.. https://doi.org/10.2217/EBO.11.358

Metastatic spread to bone : The role of chemotherapy. / Ferrari, Stefano; Palmerini, Emanuela; Mavrogenis, Andreas F.; Ruggieri, Pietro.

Advances in Bone Metastasis Management. Future Medicine Ltd., 2012. p. 19-28.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ferrari, S, Palmerini, E, Mavrogenis, AF & Ruggieri, P 2012, Metastatic spread to bone: The role of chemotherapy. in Advances in Bone Metastasis Management. Future Medicine Ltd., pp. 19-28. https://doi.org/10.2217/EBO.11.358
Ferrari S, Palmerini E, Mavrogenis AF, Ruggieri P. Metastatic spread to bone: The role of chemotherapy. In Advances in Bone Metastasis Management. Future Medicine Ltd. 2012. p. 19-28 https://doi.org/10.2217/EBO.11.358
Ferrari, Stefano ; Palmerini, Emanuela ; Mavrogenis, Andreas F. ; Ruggieri, Pietro. / Metastatic spread to bone : The role of chemotherapy. Advances in Bone Metastasis Management. Future Medicine Ltd., 2012. pp. 19-28
@inbook{c925101140f245638fc0b03e75c5a2e4,
title = "Metastatic spread to bone: The role of chemotherapy",
abstract = "Genetic profiling of tumors has revealed important regulators of the metastatic process and suggested novel targets for cancer therapeutics. Targeting the tumor cell alone is not sufficient; multimodality therapy against tumor cells, their growth factors and the essential accessory cells with which cancer cells interact is imperative. In the bone marrow and within the tumor stroma, two niches constitute highly specific, physiologically defined sites; the vascular and stromal niche. A high preponderance of tumor cells is found in the bone marrow of patients with malignancy, even in the absence of overt distant metastases. Bisphosphonates inhibit normal and pathologic osteoclast-mediated bone resorption. Denosumab inhibits the maturation of osteoclasts by binding to RANKL, protecting the bone from degradation.",
author = "Stefano Ferrari and Emanuela Palmerini and Mavrogenis, {Andreas F.} and Pietro Ruggieri",
year = "2012",
month = "3",
day = "1",
doi = "10.2217/EBO.11.358",
language = "English",
isbn = "9781780840307",
pages = "19--28",
booktitle = "Advances in Bone Metastasis Management",
publisher = "Future Medicine Ltd.",

}

TY - CHAP

T1 - Metastatic spread to bone

T2 - The role of chemotherapy

AU - Ferrari, Stefano

AU - Palmerini, Emanuela

AU - Mavrogenis, Andreas F.

AU - Ruggieri, Pietro

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Genetic profiling of tumors has revealed important regulators of the metastatic process and suggested novel targets for cancer therapeutics. Targeting the tumor cell alone is not sufficient; multimodality therapy against tumor cells, their growth factors and the essential accessory cells with which cancer cells interact is imperative. In the bone marrow and within the tumor stroma, two niches constitute highly specific, physiologically defined sites; the vascular and stromal niche. A high preponderance of tumor cells is found in the bone marrow of patients with malignancy, even in the absence of overt distant metastases. Bisphosphonates inhibit normal and pathologic osteoclast-mediated bone resorption. Denosumab inhibits the maturation of osteoclasts by binding to RANKL, protecting the bone from degradation.

AB - Genetic profiling of tumors has revealed important regulators of the metastatic process and suggested novel targets for cancer therapeutics. Targeting the tumor cell alone is not sufficient; multimodality therapy against tumor cells, their growth factors and the essential accessory cells with which cancer cells interact is imperative. In the bone marrow and within the tumor stroma, two niches constitute highly specific, physiologically defined sites; the vascular and stromal niche. A high preponderance of tumor cells is found in the bone marrow of patients with malignancy, even in the absence of overt distant metastases. Bisphosphonates inhibit normal and pathologic osteoclast-mediated bone resorption. Denosumab inhibits the maturation of osteoclasts by binding to RANKL, protecting the bone from degradation.

UR - http://www.scopus.com/inward/record.url?scp=84956791415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956791415&partnerID=8YFLogxK

U2 - 10.2217/EBO.11.358

DO - 10.2217/EBO.11.358

M3 - Chapter

AN - SCOPUS:84956791415

SN - 9781780840307

SN - 9781780841151

SP - 19

EP - 28

BT - Advances in Bone Metastasis Management

PB - Future Medicine Ltd.

ER -